[go: up one dir, main page]

DK1539746T3 - N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes - Google Patents

N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes

Info

Publication number
DK1539746T3
DK1539746T3 DK03747962T DK03747962T DK1539746T3 DK 1539746 T3 DK1539746 T3 DK 1539746T3 DK 03747962 T DK03747962 T DK 03747962T DK 03747962 T DK03747962 T DK 03747962T DK 1539746 T3 DK1539746 T3 DK 1539746T3
Authority
DK
Denmark
Prior art keywords
indole
diabetes
substituted
treatment
propionic acid
Prior art date
Application number
DK03747962T
Other languages
English (en)
Inventor
Hans Iding
Hans-Peter Maerki
Peter Mohr
Alfred Binggeli
Hans Hilpert
Beat Wirz
Uwe Grether
Roland Humm
Bernd Kuhn
Markus Meyer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1539746T3 publication Critical patent/DK1539746T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
DK03747962T 2002-09-12 2003-09-04 N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes DK1539746T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02020477 2002-09-12
PCT/EP2003/009819 WO2004024726A1 (en) 2002-09-12 2003-09-04 N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes

Publications (1)

Publication Number Publication Date
DK1539746T3 true DK1539746T3 (da) 2007-03-26

Family

ID=31985028

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03747962T DK1539746T3 (da) 2002-09-12 2003-09-04 N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes

Country Status (29)

Country Link
US (1) US6890947B2 (da)
EP (1) EP1539746B1 (da)
JP (1) JP4286782B2 (da)
KR (1) KR100645684B1 (da)
CN (1) CN100577660C (da)
AR (1) AR041218A1 (da)
AT (1) ATE345340T1 (da)
AU (1) AU2003267041B2 (da)
BR (1) BR0314261A (da)
CA (1) CA2494601C (da)
DE (1) DE60309719T2 (da)
DK (1) DK1539746T3 (da)
ES (1) ES2275105T3 (da)
GT (1) GT200300194A (da)
HR (1) HRP20050212A2 (da)
MX (1) MXPA05002704A (da)
MY (1) MY135646A (da)
NO (1) NO20050667L (da)
NZ (1) NZ537979A (da)
PA (1) PA8581701A1 (da)
PE (1) PE20050050A1 (da)
PL (1) PL375878A1 (da)
PT (1) PT1539746E (da)
RU (1) RU2296759C2 (da)
SI (1) SI1539746T1 (da)
TW (1) TWI248933B (da)
UY (1) UY27975A1 (da)
WO (1) WO2004024726A1 (da)
ZA (1) ZA200501273B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
ATE339205T1 (de) * 2003-04-17 2006-10-15 Kalypsys Inc (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
US7405236B2 (en) * 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NO20083270L (no) * 2008-07-23 2010-01-25 Thia Medica As Indolforbindelser
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) * 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
EP0648212B1 (en) 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazole and benzothiazole derivatives as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
EP0820441B1 (en) * 1995-04-10 2002-06-26 Fujisawa Pharmaceutical Co., Ltd. INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
WO1997027857A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Antidiabetic agents
AU719994B2 (en) * 1996-12-10 2000-05-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
DE19711616A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) * 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
DE69815008T2 (de) 1997-09-19 2004-04-01 Ssp Co., Ltd. Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
GB9817118D0 (en) 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
BR9912979B1 (pt) 1998-08-14 2010-09-21 composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
JP3774118B2 (ja) 1998-08-14 2006-05-10 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤を含む製薬学的組成物
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DE60026404T2 (de) * 1999-08-02 2006-10-19 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Benzothiophen-Derivaten
DE60128475T2 (de) * 2000-07-25 2008-02-07 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes
EA200300286A1 (ru) 2000-08-23 2003-08-28 Эли Лилли Энд Компани Агонисты активируемых пероксисомальным пролифератором рецепторов
DE10117090B4 (de) * 2001-04-06 2013-08-14 Dr. Ing. H.C. F. Porsche Aktiengesellschaft Wassergekühlte, mehrzylindrige Brennkraftmaschine
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
WO2003040114A1 (en) * 2001-11-06 2003-05-15 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
AU2002359160A1 (en) 2001-12-20 2003-07-09 Biovitrum Ab PIPAZOLO (1,5-a) PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR

Also Published As

Publication number Publication date
TWI248933B (en) 2006-02-11
NZ537979A (en) 2007-08-31
JP2006503029A (ja) 2006-01-26
DE60309719D1 (de) 2006-12-28
PL375878A1 (en) 2005-12-12
ZA200501273B (en) 2006-08-30
RU2296759C2 (ru) 2007-04-10
UY27975A1 (es) 2004-03-31
AU2003267041B2 (en) 2007-03-29
AR041218A1 (es) 2005-05-11
PT1539746E (pt) 2007-02-28
KR20050042809A (ko) 2005-05-10
CN100577660C (zh) 2010-01-06
EP1539746A1 (en) 2005-06-15
CA2494601A1 (en) 2004-03-25
NO20050667L (no) 2005-06-08
JP4286782B2 (ja) 2009-07-01
AU2003267041A1 (en) 2004-04-30
WO2004024726A1 (en) 2004-03-25
TW200418845A (en) 2004-10-01
CA2494601C (en) 2009-09-29
PE20050050A1 (es) 2005-02-18
CN1681808A (zh) 2005-10-12
RU2005110921A (ru) 2006-01-20
HRP20050212A2 (en) 2006-05-31
BR0314261A (pt) 2005-07-26
PA8581701A1 (es) 2004-04-23
US20040053979A1 (en) 2004-03-18
DE60309719T2 (de) 2007-09-20
US6890947B2 (en) 2005-05-10
ES2275105T3 (es) 2007-06-01
ATE345340T1 (de) 2006-12-15
EP1539746B1 (en) 2006-11-15
MY135646A (en) 2008-06-30
MXPA05002704A (es) 2005-05-05
KR100645684B1 (ko) 2006-11-15
GT200300194A (es) 2004-04-15
SI1539746T1 (sl) 2007-04-30

Similar Documents

Publication Publication Date Title
DK1471057T3 (da) Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
DK1651622T3 (da) Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
DK1551511T5 (da) Heterocykliske aromatiske forbindelser, der er anvendelige som væksthormonsekretagoger
DK1539746T3 (da) N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes
PL1636190T3 (pl) Trwały kryształ związku 4-oksochinoliny
DK1756084T3 (da) Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
DK1703909T3 (da) 1-benzoyl-piperazinderivater som glycinoptagelsesinhibitorer til behandling af psykoser
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1678185T3 (da) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazolforbindelser til behandling af tuberkulose
DE602004026320D1 (de) Nichtwässrige flüssige zahnbleichzusammensetzung
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1954690T3 (da) Benzamidforbindelser, der er anvendelige som inhibitorer af histondeacetylase
DK1954668T3 (da) Homo- og heterocykliske forbindelser, der er egnede som CETP-inhibitorer
DK1617834T3 (da) Anvendelse af en farmaceutisk sammensætning indeholdende mælkesyre eller lactat og kalium til behandling af hjerneödem eller hjerneskade
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
DK1720848T3 (da) Derivater af alkylpiperazin- og alkylhomopiperazincarboxylater, fremgangsmåde til fremstilling heraf og anvendelse heraf som inhibitorer af enzymet FAAH
DK1599452T3 (da) 3- (2-phenyloxazol- 4-ylmethoxy) - cyclohexylmethoxyeddikesyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og atherosklerosw
IS7858A (is) Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD)
DK1551814T3 (da) Chirale oxazol-arylpropionsyrederivater og anvendelse deraf som ppar-agnister
DK1519928T3 (da) Fremgangsmåde til fremstilling af heterocykliske fluoralkenylsulfoner
DK1828166T3 (da) Hydantoinderivater, der kan anvendes som metalloproteinase-inhibitorer
DK2845594T3 (da) Anvendelse af dihydroimidazoloner til behandlingen af hunde.
DK1692137T3 (da) Fremgangsmåde til fremstilling af tubulinininhibitorer